"Cancer is a complex disease and to treat it effectively we need a greater understanding of the activity that takes place at the molecular level," said Lewis Cantley, Ph.D., director of the cancer center at Beth Israel Deaconess Medical Center and one of the scientific committee chairpersons of the conference. "The research presented at this conference will bring us closer to that understanding."
Experts from the world's leading cancer centers and pharmaceutical companies will discuss innovations in drug development, target selection and the impact of new discoveries in molecular and cellular biology.
Understanding the pathways and mechanisms that cause cancer and regulate the biological behavior of tumor cells has already led to the development of numerous new agents. This conference, now in its second decade, has been organized to reflect the many recent advances in the early development of promising new compounds.
During the conference, the American Association for Cancer Research will host several press briefings: "Drugs in the Pipeline," "Emerging Therapies in Pancreatic Cancer" and "Markers of Prognosis."
For the latest information on the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference, follow the AACR on Twitter using the hashtag #AACRTargets09